Anti-cancer antibody trastuzumab-melanotransferrin conjugate (BT2111) for the treatment of metastatic HER2+ breast cancer tumors in the brain: An in-vivo study

PURPOSE: The ability of human melanotransferrin (hMTf) to carry a therapeutic concentration of trastuzumab (BTA) in the brain after conjugation (in the form of trastuzumab-melanotransferrin conjugate, BT2111 conjugate) was investigated by measuring the reduction of the number and size of metastatic...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Pharm Res
Autori principali: Nounou, Mohamed Ismail, Adkins, Chris E., Rubinchik, Evelina, Terrell-Hall, Tori B, Afroz, Mohamed, Vitalis, Tim, Gabathuler, Reinhard, Tian, Mei Mei, Lockman, Paul R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5267937/
https://ncbi.nlm.nih.gov/pubmed/27528392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11095-016-2015-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi